Al Garfall
@AlGarfall
Oncologist @PennMedicine @PennCancer specializing in multiple myeloma and cellular immunotherapy.
I Have Immense Faith in Oncologists’ Abilities to De-Escalate Bela-Maf - Rahul Banerjee (@RahulBanerjeeMD) @AlGarfall @JoshuaRichterMD oncodaily.com/opinion/rahul-… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #Myeloma @CancerWorldmag
Yesterday Blenrep was approved in Canada - today Blenrep was approved in the EU. This myeloma patient and research advocate hopes that by October the @US_FDA GIVES Blenrep the green light too. #mmsm gsk.com/en-gb/media/pr…
Sequential BCMA CAR-T Cell Therapy (cilta-cel in patients relapsing after ide-cel) in RRMM. N=10, VGPR: 100%, MRD-ve: 60%. 6-month PFS: 64.8% #mmsm #bmtsm @BloodPortfolio ashpublications.org/bloodadvances/…
In a trial like this, really important to see the pfs not just mrd. We learned from the forte study that while delaying transplant had similar depth of response at an early time point, the pfs was clearly better for the transplant arm.
My take on this trial below. #ASCO25 The nuance is that this trial similar to prior trials like DETERMINATION demonstrate not everyone needs transplant upfront. But… 👇
Very nice study by @SusanBal9 & @End_myeloma demonstrating marked reduction in MRD burden after auto SCT in patients receiving quad induction for myeloma #mmsm rdcu.be/ejHBb
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma @BloodJournal #mmsm ✅ modakafusp: immunocytokine directing interferon-α to CD38-positive cells ✅ ~1/2 with prior BCMA ttt ✅median FU: 7.6 mo ✅ORR: 41% in…
Hence, limited duration treatment needs to be evaluated for these drugs in #mmsm @AlGarfall is leading LimiTEC study which studies limited duration bispecific. Also open at @uiowa @strouse_chris and Columbia @rajshekharucms
4/ ⛔️Discontinuation and dose reduction: - 43% required treatment interruption, mainly due to toxicities (the challenge of continuous drug use due to unique toxicities and cytopenias) #mmsm #myeloma #MedEd #medtwitter @OncoAlert @USMIRCNEWS #USMIRC #سرطان_الدم #المايلوما
NIH scientists have a cancer breakthrough. Layoffs are delaying it. wapo.st/42yttHQ
Alfred L. Garfall, MD, (@AlGarfall) emphasizes the critical importance of the National Institutes of Health funding for biomedical research. @PennMedicine @PennCancer hubs.li/Q039lvDs0
The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy ashpublications.org/blood/article-…
Novel interferon-based antimyeloma activity ashpublications.org/blood/article/… #mmsm #bmtsm
Modakafusp alfa delivers interferon alfa signaling to CD38+ myeloma, and has a 43% ORR in R/R MM at the recommended phase 2 doses, with primarily hematologic toxicities ashpublications.org/blood/article/… #mmsm @JKaufmanMD @AtrashShebli
It's time for the #FiveUnder5! Check out the top 5️⃣ #oncology clips of the week: onclive.com/view/five-unde… @WilliamOhMD @SmilowCancer @AlGarfall @PennCancer @amerseburger @shilpaonc @CleclinicMD @VUMChealth #pcsm #mmsm #lymsm #oncology #medtwitter
This is exactly right. Gutting the NIH will lead to a rapid labor shortage and all these jobs going overseas
Hey Pharma, Biotech, are you aware of the massive labor shortage that’s coming your way?
Urge Congress to Support NIH and Protect Medical Research votervoice.net/Shares/BAAAAAI…